Slowing the progression of Alzheimer’s disease; what works?
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is an age-related progressive dementia, which is increasing in prevalence world-wide. Typically affecting short-term memory at onset, this devastating illness advances to impair all aspects of cognition, as well as non-cognitive domains. Although much effort has been made in recent years to develop disease-modifying treatments, medications which provided promising results in pre-clinical research have so far faltered in human clinical trials. Attention has recently shifted into trying to identify preventative measures that may delay the onset of the illness. Preventative factors include physical activity, proper diet, cognitive stimulation and the management of conditions such as hypertension, diabetes and obesity. However, it remains imperative to identify approaches that may help patients already diagnosed with the illness. Alongside pharmacological research, much work has been done on uncovering strategies which may slow down the progression of AD. This review aims to summarize evidence supporting or refuting methods impacting on the progression of the disease. AD remains a chronic and serious condition, therefore any intervention delaying the onset of moderate/severe symptoms will have a significant impact on patients and their families.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive reserve in ageing and Alzheimer's disease
Stern, Y. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70191-6 · Cited by 3,557 · cited 1×
“While cognitive reserve may have a protective effect against early presentation of symptoms, this may be lost once conditions advance, as higher levels of cognitive reserve mask the consequences of early pathology (Stern, 2012).”
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906 · cited 1×
“Little difference has been found between the three AChEIs in regards to their effectiveness (Birks, 2006).”
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · cited 1×
“Disease-modifying drug treatments remain evasive, and AD has one of the lowest success rates for drug approval into Phase three testing (Cummings et al. 2014).”
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Cytokine-Associated Emotional and Cognitive Disturbances in Humans
Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., & Pollmächer, T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.5.445 · Cited by 1,365
Cited by
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott, I. T., & Head, E. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0132-6 · Cited by 383
Neighborhood Environment and Cognition in Older Adults: A Systematic Review
Besser, L. M., McDonald, N. C., Song, Y., Kukull, W. A., & Rodriguez, D. A. (2017) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2017.02.013 · Cited by 268
Gosztolya, G., Vincze, V., Tóth, L., Pákáski, M., Kálmán, J., & Hoffmann, I. (2019) · Computer Speech & Language · doi:10.1016/j.csl.2018.07.007 · Cited by 196
Nutrition and AGE‐ing: Focusing on Alzheimer’s Disease
Abate, G., Marziano, M., Rungratanawanich, W., Memo, M., & Uberti, D. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/7039816 · Cited by 103
Assessing Alzheimer’s disease from speech using the i-vector approach
Egas López, J. V., Tóth, L., Hoffmann, I., Kálmán, J., Pákáski, M., & Gosztolya, G. (2019) · Lecture notes in computer science · doi:10.1007/978-3-030-26061-3_30 · Cited by 18
“The early diagnosis of the disease could lead to a more effective confrontation of the AD in order to slow down its development; this stage of diagnosis is difficult to achieve [14,24].”
BackgroundCognitive Decline in Alzheimer’s Disease Is Not Associated with APOE
Katzourou, I., Initiative, T. A. D. N., Leonenko, G., Ivanov, D., Meggy, A., Marshall, R., Sims, R., Williams, J., Holmans, P., & Escott-Price, V. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-210685 · Cited by 9
“Based on existing literature, there is a suggestion that patients with EOAD tend to deteriorate faster [39–42], although there are studies showing no association of rate of decline with age at disease onset [43], and others showing that patients with an earlier onset decline slower [44], as found…”
Metadata
- Authors
- Nelson, L., & Tabet, N.
- Venue
- Ageing Research Reviews
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 23
- Issue
- Pt B
- Pages
- 193-209
- ISSN
- 1568-1637 (ISSN-L)
- OpenAlex
- W1031113081
- Cited by
- 109
- References
- 60
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.